Faiyaz Ahmad

Faiyaz Ahmad

Auto-generated profile, based on publicly available information

Faiyaz Ahmad

Department of Zoology, Langat Singh College, Baba Saheb Bhim Rao Ambedkar Bihar University, Muzaffarpur, Bihar, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SSSanaa Sharari
Sanaa Sharari
MAMohamad Abou-Alloul
Mohamad Abou-Alloul
KHKhalid Hussain
Khalid Hussain
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan
Accumulation of glycogen in the kidney and liver is the main feature of Fanconi–Bickel Syndrome (FBS), a rare disorder of carbohydrate metabolism inherited in an autosomal recessive manner due to SLC2A2 gene mutations. Missense, nonsense, frame-shift (fs), in-frame indels, splice site, and compound heterozygous variants have all been identified in SLC2A2 gene of FBS cases. Approximately 144 FBS cases with 70 different SLC2A2 gene variants have been reported so far. SLC2A2 encodes for glucose transporter 2 (GLUT2) a low affinity facilitative transporter of glucose mainly expressed in tissues playing important roles in glucose homeostasis, such as renal tubular cells, enterocytes, pancreatic β-cells, hepatocytes and discrete regions of the brain. Dysfunctional mutations and decreased GLUT2 expression leads to dysglycaemia (fasting hypoglycemia, postprandial hyperglycemia, glucose intolerance, and rarely diabetes mellitus), hepatomegaly, galactose intolerance, rickets, and poor growth. The molecular mechanisms of dysglycaemia in FBS are still not clearly understood. In this review, we discuss the physiological roles of GLUT2 and the pathophysiology of mutants, highlight all of the previously reported SLC2A2 mutations associated with dysglycaemia, and review the potential molecular mechanisms leading to dysglycaemia and diabetes mellitus in FBS patients.

17 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSungJun Park
SungJun Park
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan
RBRobert J. Bahde
Robert J. Bahde
APAndrew Philp
Andrew Philp
JKJeonghan Kim
Jeonghan Kim
JCJay H. Chung
Jay H. Chung
AMP-activated protein kinase (AMPK) is an evolutionarily conserved energy sensor. Activation of AMPK leads to a number of metabolic benefits, including improved mitochondrial function in skeletal muscle and lowering of serum glucose levels in type-2 diabetes models. However, direct activation of AMPK leads to cardiac enlargement, and an alternative strategy that activates AMPK without affecting the heart is needed. Inhibition of phosphodiesterase 4 (PDE4), which is poorly expressed in the human heart, activates AMPK in other tissues. In a screen to identify novel PDE4 inhibitors, we discovered compound CBU91, which is 5–10 fold more potent than rolipram, the best characterized PDE4 inhibitor. CBU91, like rolipram, is able to activate AMPK and Sirt1 and increase mitochondrial function in myotubes. These findings suggest that activation of AMPK in myotubes is a general property of PDE4 inhibition and that PDE4 inhibition may activate AMPK in metabolically relevant tissues without affecting the heart.

22 July 2022
Verified
Book Chapter
Closed access
DKDhiraj Kumar
Dhiraj Kumar
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan